On June 4, 2026, the U.S. Supreme Court held in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, that routine generic drug marketing activities, including skinny labels, standard therapeutic equivalence descriptions and investor-oriented press releases, do not necessarily constitute active inducement of patent infringement under 35 U.S.C. § 271(b). Writing for a unanimous Court, Justice Ketanji Brown Jackson rejected the approach by the U.S. Court of Appeals for the Federal Circuit of asking whether a physician “could read” a generic manufacturer’s statements as instructions to infringe. The Court instead held that the proper inquiry is whether the defendant “actively encouraged infringing uses.” Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., 608 U.S. —, slip op. at 2 (2026).
The Court emphasized that inducement requires “affirmative” steps, not mere compliance with regulatory requirements, omissions or vague statements that might lead others to infringe. Hikma, 608 U.S. at 11-12 (citing Global-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754, 760 (2011); Twitter, Inc. v. Taamneh, 598 U.S. 471, 489 (2023)). This is a significant decision for branded manufacturers working to maintain exclusivity for additional indications and generic manufacturers looking to enter the market when at least one indication is off-patent.
The case arose after Hikma obtained FDA approval to market generic icosapent ethyl under a “skinny label” covering only the unpatented severe hypertriglyceridemia indication, carving out Amarin’s patented cardiovascular-risk-reduction method of use. Id. at 1-2. Amarin alleged that the totality of Hikma’s communications, including its skinny label, patient information leaflet, website and press releases, actively induced healthcare providers to prescribe Hikma’s generic drug for the patented cardiovascular indication. Id. The Federal Circuit reversed the district court’s dismissal, finding it “at least plausible that a physician could read” Hikma’s statements “as an instruction or encouragement to infringe.” Id. at 2.
The Court’s analysis addressed and rejected each category of Hikma’s statements that Amarin cited as evidence of inducement. First, the Court found that several of Hikma’s statements had an “obvious alternative explanation”: compliance with the law or standard industry practice. Id. at 10-11 (quoting Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 567 (2007)). For instance, Hikma’s label was required by statute to be identical to Amarin’s except for the carved-out use, and describing a generic drug as the “generic equivalent” of the brand-name product is “normal industry practice.” Id. at 11 (citing Inwood Laboratories, Inc. v. Ives Laboratories, Inc., 456 U.S. 844, 847–848 (1982)).
Second, the Court held that Amarin could not rely on “mere omissions, inactions, or nonfeasance,” such as the skinny label’s omission of the CV Limitation of Use or press releases’ failure to mention that Hikma’s approved use was limited to the lesser-known SH indication, to plausibly allege active inducement. Id. at 11-12 (quoting Twitter, Inc., 598 U.S. at 489). Third, the Court found that Hikma’s remaining statements were too “vague” to support inducement liability, explaining that the patient information leaflet’s warnings, the website’s description of the therapeutic category as “hypertriglyceridemia,” the AB rating and the press releases’ inclusion of sales figures attributable to both indications were all “implausibly roundabout ways” to induce infringement. Id. at 12-14 (citing Takeda Pharms. U.S.A., Inc. v. West-Ward Pharm. Corp., 785 F.3d 625, 632 (Fed. Cir. 2015)). Notably, while the Court rejected the argument that inducement must be “express,” it emphasized that whether implicit or explicit, the inducement must be “clear” to the relevant audience and “affirmative.” Id. at 10 (citing Grokster, 545 U.S. at 937).
This decision emphasizes that generic manufacturers have significant “breathing room” to market their products, including through skinny labels, standard industry descriptions and routine press communications, without significant concern that properly following FDA labeling requirements or ordinary commercial practices will be construed as active inducement of patent infringement. The Court’s explicit rejection of the Federal Circuit’s “could be read” standard in favor of a more demanding “actively encouraged” standard — requiring allegations beyond “a sheer possibility” of unlawful conduct, Id. at 10 (quoting Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009)) — raises the bar for branded manufacturers seeking to bring induced-infringement claims at the pleading stage. But the Court’s acknowledgment that “implicit encouragement” may still qualify as active inducement softens an otherwise bright-line rule. And the Court did not foreclose the possibility that other facts could have been pled to satisfy this standard.
McGuireWoods continues to monitor developments stemming from this decision. For questions, contact the authors or a member of the Intellectual Property Practice Group.